Literature DB >> 24752008

Intravitreal dexamethasone implant for refractory macular edema secondary to vitrectomy for macular pucker.

Claudio Furino1, Francesco Boscia, Nicola Recchimurzo, Carlo Sborgia, Giovanni Alessio.   

Abstract

PURPOSE: To study the efficacy of a single 0.7 mg dexamethasone intravitreal implant in vitrectomized eyes with refractory macular edema secondary to combined cataract extraction and macular pucker removal.
METHODS: In 8 eyes of 8 consecutive patients with refractory macular edema secondary to combined cataract extraction and 25-gauge vitrectomy with internal limiting membrane peeling for macular pucker removal, the injection of the 0.7 mg dexamethasone implant was performed. Best-corrected visual acuity, central retinal thickness measured by spectral domain optical coherence tomography, and intraocular pressure were evaluated at baseline, 1 month, and 6 months.
RESULTS: After a mean follow-up of 6.75 ± 0.71 months, best-corrected visual acuity was significantly increased (P < 0.0001) from 20/50 to 20/23 (P < 0.0001), mean central retinal thickness decreased significantly from 439 ± 45 μm to 296 ± 49 μm (P < 0.0001), and intraocular pressure changed significantly (P = 0.02) from 14.63 ± 1.19 to 16 ± 0.93. In no case postoperative hypotony or other complication was observed.
CONCLUSION: A single injection of the 0.7 mg dexamethasone intravitreal implant resulted effective in the treatment of refractory macular edema secondary to combined cataract extraction and vitrectomy for macular pucker removal allowing a stable visual acuity recovery.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24752008     DOI: 10.1097/IAE.0000000000000105

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  13 in total

1.  RECALCITRANT CYSTOID MACULAR EDEMA AFTER PARS PLANA VITRECTOMY.

Authors:  Mostafa R Alam; Cheryl A Arcinue; Nadia B Mendoza; William R Freeman
Journal:  Retina       Date:  2016-07       Impact factor: 4.256

Review 2.  [Statement of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on the development, diagnostics and treatment of epiretinal gliosis : Status October 2020].

Authors: 
Journal:  Ophthalmologe       Date:  2021-02       Impact factor: 1.059

3.  [Intravitreal dexamethasone implant for treatment of persistent postoperative macular edema after vitrectomy].

Authors:  L-O Hattenbach; C Kuhli-Hattenbach; C Springer; J Callizo; H Hoerauf
Journal:  Ophthalmologe       Date:  2016-07       Impact factor: 1.059

Review 4.  Pars plana vitrectomy combined with phacoemulsification versus pars plana vitrectomy only for treatment of phakic rhegmatogenous retinal detachment: a systematic review and meta-analysis.

Authors:  Ahmad Mirshahi; Elias Khalilipour; Hooshang Faghihi; Hamid Riazi-Esfahani; Romina Mirshahi; Hadi Z Mehrjardi; Ehsan Najibzadeh; Abdulrahim Amini; Amin Nabavi
Journal:  Int Ophthalmol       Date:  2022-08-19       Impact factor: 2.029

5.  Mid-term safety and effectiveness of intravitreal dexamethasone implant to treat persistent cystoid macular edema in vitrectomized eyes for bacterial endophthalmitis.

Authors:  Giancarlo Sborgia; Alfredo Niro; Valentina Pastore; Rosa Anna Favale; Alessandra Sborgia; Samuele Gigliola; Gianluigi Giuliani; Maria Oliva Grassi; Marco Coassin; Francesco Aiello; Cristiana Iaculli; Michele Reibaldi; Francesco Boscia; Giovanni Alessio
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-07       Impact factor: 3.535

6.  Evaluation of intraoperative slow-release dexamethasone implant combined with idiopathic epiretinal membrane removal.

Authors:  Alfonso Savastano; Alice Bitossi; Fabrizio Giansanti; Lorenzo Vannozzi; Tomaso Caporossi; Francesco Barca; Gianni Virgili; Gloria Gambini; Umberto De Vico; Patrizio Bernardinelli; Maria Cristina Savastano; Stanislao Rizzo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-09-06       Impact factor: 3.117

7.  Dexamethasone Intravitreal Implant (Ozurdex) for Long-Term Macular Edema after Epiretinal Membrane Peeling Surgery.

Authors:  Yo-Chen Chang; Pei-Kang Liu; Tzu-En Kao; Horng-Jiun Wu; Kai-Chun Cheng; Kuo-Jen Chen; Kwou-Yeung Wu; Wen-Chuan Wu
Journal:  J Ophthalmol       Date:  2018-12-10       Impact factor: 1.909

Review 8.  Widening use of dexamethasone implant for the treatment of macular edema.

Authors:  Vincenza Bonfiglio; Michele Reibaldi; Matteo Fallico; Andrea Russo; Alessandra Pizzo; Stefano Fichera; Carlo Rapisarda; Iacopo Macchi; Teresio Avitabile; Antonio Longo
Journal:  Drug Des Devel Ther       Date:  2017-08-16       Impact factor: 4.162

9.  Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema.

Authors:  Claudio Furino; Francesco Boscia; Alfredo Niro; Ermete Giancipoli; Maria Oliva Grassi; Giuseppe D'amico Ricci; Francesco Blasetti; Michele Reibaldi; Giovanni Alessio
Journal:  J Ophthalmol       Date:  2017-08-13       Impact factor: 1.909

10.  Evaluation of Functional Outcomes and OCT-Biomarkers after Intravitreal Dexamethasone Implant for Postoperative Cystoid Macular Edema in Vitrectomized Eyes.

Authors:  Sigrid Freissinger; Efstathios Vounotrypidis; Armin Wolf; Karsten U Kortuem; Mehdi Shajari; Filippos Sakkias; Tina Herold; Siegfried G Priglinger; Wolfgang J Mayer
Journal:  J Ophthalmol       Date:  2020-04-28       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.